2026 Q3 - tulosraportti
11 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,20%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 2 | ||
| 2 121 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenNew CagriSema data shows stronger results - both in terms of weight loss and quality of life. Novo Nordisk has presented new analyses from the phase 3 trial REDEFINE 1 at ObesityWeek 2026, which provide a more nuanced and positive picture of the effect of CagriSema. The new analyses particularly highlight two interesting results: Rapid weight loss with strong long-term results: As many as 67.8% of participants achieved at least 5% weight loss already within the first 8 weeks. This group had an average weight loss of a full 25.4% after 68 weeks compared to 17.8% among those who responded later. Improved physical and psychosocial function: The new data also show that 73.1% experienced a meaningful improvement in physical function compared to 49.1% in the placebo group. For psychosocial function, the figures were 69% and 42.1% respectively. The improvements in physical function could already be seen from week 8. What is new about the analyses is that they go beyond the previously known weight loss results and focus on how fast the treatment works and how the weight loss can make a noticeable difference in everyday life. The results strengthen interest in CagriSema's potential as a treatment for obesity, where the benefit is not only about fewer kilos, but also about better physical function and quality of life.
Whether it moves wildly on the share price I am unsure about. But a little is also better than nothing. Well upwards hopefully 🤞- ·1 t sitten · MuokattuNovo Nordisk: Oral Wegovy (the pill) shows strong results💪 New real-world data presented at ObesityWeek 2026 shows that patients taking Novo Nordisk's Wegovy in pill form lost an average of 6.2 % of their body weight after just three months. The study included 5,872 adult patients who had not previously used weight loss medication. Key findings: -Average weight loss of 6.2 % corresponding to 6.3 kg. -Approximately 60 % lost at least 5 % of their body weight. -About one in six achieved at least 10 % weight loss. -Average starting weight was 103 kg. The results exceed Novo Nordisk's phase 3 results, where patients lost 5.5 % after 12 weeks. That is almost 13 % better!! Strong position in the US market Oral obesity treatments are rapidly gaining ground in the US and now account for approximately one-third of obesity medication prescriptions. According to the company's own presentations, Novo Nordisk has secured more than 80 % of new prescriptions for oral weight loss medication. Comparison with Eli Lilly Oral Wegovy has shown approximately 14 % weight loss over 64 weeks in clinical trials. By comparison, Lilly's treatment has shown approximately 11 % over 72 weeks. However, the results stem from different studies and are not directly comparable.
That studies are not directly comparable usually doesn't worry LLY... but thanks for the thoroughness. 
·2 t sittenGreat that it is soon Monday, then we will reach 100 totally useless posts from the boss in here, instead of daily 50 posts here this weekend 🎉😂😂😂
·18 t sittenYes , but you can also put on some big headphones - to block out food noise. 🎷🎷 Fantastico with this Novo.I have all those you decide I have, so it lives completely up to your conspiracy theories 😂😂😂- ·19 t sitten · MuokattuObesityWeek® 2026 Wegovy not only provides weight loss - but perhaps also more mental peace regarding food! New studies show that semaglutide can reduce so-called food noise - the constant thoughts about food, hunger, and cravings. In the studies, a reduction was seen already after the first month with Wegovy injections, and with oral semaglutide (tablets), food noise decreased by approx. 25 % after three months. As many as 86.4 % experienced at least one improvement. This indicates that Wegovy can provide an extra benefit: less food noise, fewer thoughts about food, and more mental freedom in everyday life.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
11 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,20%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenNew CagriSema data shows stronger results - both in terms of weight loss and quality of life. Novo Nordisk has presented new analyses from the phase 3 trial REDEFINE 1 at ObesityWeek 2026, which provide a more nuanced and positive picture of the effect of CagriSema. The new analyses particularly highlight two interesting results: Rapid weight loss with strong long-term results: As many as 67.8% of participants achieved at least 5% weight loss already within the first 8 weeks. This group had an average weight loss of a full 25.4% after 68 weeks compared to 17.8% among those who responded later. Improved physical and psychosocial function: The new data also show that 73.1% experienced a meaningful improvement in physical function compared to 49.1% in the placebo group. For psychosocial function, the figures were 69% and 42.1% respectively. The improvements in physical function could already be seen from week 8. What is new about the analyses is that they go beyond the previously known weight loss results and focus on how fast the treatment works and how the weight loss can make a noticeable difference in everyday life. The results strengthen interest in CagriSema's potential as a treatment for obesity, where the benefit is not only about fewer kilos, but also about better physical function and quality of life.Whether it moves wildly on the share price I am unsure about. But a little is also better than nothing. Well upwards hopefully 🤞
- ·1 t sitten · MuokattuNovo Nordisk: Oral Wegovy (the pill) shows strong results💪 New real-world data presented at ObesityWeek 2026 shows that patients taking Novo Nordisk's Wegovy in pill form lost an average of 6.2 % of their body weight after just three months. The study included 5,872 adult patients who had not previously used weight loss medication. Key findings: -Average weight loss of 6.2 % corresponding to 6.3 kg. -Approximately 60 % lost at least 5 % of their body weight. -About one in six achieved at least 10 % weight loss. -Average starting weight was 103 kg. The results exceed Novo Nordisk's phase 3 results, where patients lost 5.5 % after 12 weeks. That is almost 13 % better!! Strong position in the US market Oral obesity treatments are rapidly gaining ground in the US and now account for approximately one-third of obesity medication prescriptions. According to the company's own presentations, Novo Nordisk has secured more than 80 % of new prescriptions for oral weight loss medication. Comparison with Eli Lilly Oral Wegovy has shown approximately 14 % weight loss over 64 weeks in clinical trials. By comparison, Lilly's treatment has shown approximately 11 % over 72 weeks. However, the results stem from different studies and are not directly comparable.That studies are not directly comparable usually doesn't worry LLY... but thanks for the thoroughness.
- ·2 t sittenGreat that it is soon Monday, then we will reach 100 totally useless posts from the boss in here, instead of daily 50 posts here this weekend 🎉😂😂😂
- ·18 t sittenYes , but you can also put on some big headphones - to block out food noise. 🎷🎷 Fantastico with this Novo.I have all those you decide I have, so it lives completely up to your conspiracy theories 😂😂😂
- ·19 t sitten · MuokattuObesityWeek® 2026 Wegovy not only provides weight loss - but perhaps also more mental peace regarding food! New studies show that semaglutide can reduce so-called food noise - the constant thoughts about food, hunger, and cravings. In the studies, a reduction was seen already after the first month with Wegovy injections, and with oral semaglutide (tablets), food noise decreased by approx. 25 % after three months. As many as 86.4 % experienced at least one improvement. This indicates that Wegovy can provide an extra benefit: less food noise, fewer thoughts about food, and more mental freedom in everyday life.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 2 | ||
| 2 121 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
11 päivää sitten
‧1 t 3 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,20%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenNew CagriSema data shows stronger results - both in terms of weight loss and quality of life. Novo Nordisk has presented new analyses from the phase 3 trial REDEFINE 1 at ObesityWeek 2026, which provide a more nuanced and positive picture of the effect of CagriSema. The new analyses particularly highlight two interesting results: Rapid weight loss with strong long-term results: As many as 67.8% of participants achieved at least 5% weight loss already within the first 8 weeks. This group had an average weight loss of a full 25.4% after 68 weeks compared to 17.8% among those who responded later. Improved physical and psychosocial function: The new data also show that 73.1% experienced a meaningful improvement in physical function compared to 49.1% in the placebo group. For psychosocial function, the figures were 69% and 42.1% respectively. The improvements in physical function could already be seen from week 8. What is new about the analyses is that they go beyond the previously known weight loss results and focus on how fast the treatment works and how the weight loss can make a noticeable difference in everyday life. The results strengthen interest in CagriSema's potential as a treatment for obesity, where the benefit is not only about fewer kilos, but also about better physical function and quality of life.Whether it moves wildly on the share price I am unsure about. But a little is also better than nothing. Well upwards hopefully 🤞
- ·1 t sitten · MuokattuNovo Nordisk: Oral Wegovy (the pill) shows strong results💪 New real-world data presented at ObesityWeek 2026 shows that patients taking Novo Nordisk's Wegovy in pill form lost an average of 6.2 % of their body weight after just three months. The study included 5,872 adult patients who had not previously used weight loss medication. Key findings: -Average weight loss of 6.2 % corresponding to 6.3 kg. -Approximately 60 % lost at least 5 % of their body weight. -About one in six achieved at least 10 % weight loss. -Average starting weight was 103 kg. The results exceed Novo Nordisk's phase 3 results, where patients lost 5.5 % after 12 weeks. That is almost 13 % better!! Strong position in the US market Oral obesity treatments are rapidly gaining ground in the US and now account for approximately one-third of obesity medication prescriptions. According to the company's own presentations, Novo Nordisk has secured more than 80 % of new prescriptions for oral weight loss medication. Comparison with Eli Lilly Oral Wegovy has shown approximately 14 % weight loss over 64 weeks in clinical trials. By comparison, Lilly's treatment has shown approximately 11 % over 72 weeks. However, the results stem from different studies and are not directly comparable.That studies are not directly comparable usually doesn't worry LLY... but thanks for the thoroughness.
- ·2 t sittenGreat that it is soon Monday, then we will reach 100 totally useless posts from the boss in here, instead of daily 50 posts here this weekend 🎉😂😂😂
- ·18 t sittenYes , but you can also put on some big headphones - to block out food noise. 🎷🎷 Fantastico with this Novo.I have all those you decide I have, so it lives completely up to your conspiracy theories 😂😂😂
- ·19 t sitten · MuokattuObesityWeek® 2026 Wegovy not only provides weight loss - but perhaps also more mental peace regarding food! New studies show that semaglutide can reduce so-called food noise - the constant thoughts about food, hunger, and cravings. In the studies, a reduction was seen already after the first month with Wegovy injections, and with oral semaglutide (tablets), food noise decreased by approx. 25 % after three months. As many as 86.4 % experienced at least one improvement. This indicates that Wegovy can provide an extra benefit: less food noise, fewer thoughts about food, and more mental freedom in everyday life.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 2 | ||
| 2 121 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt